Donald A. Simone
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Donald A. Simone has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
Sergey G. Khasabov
Department of Diagnostic and Biological Sciences, University of Minnesota
9 shared publications- Megan L. Uhelski
Department of Pain Medicine Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
6 shared publications Iryna A. Khasabova
Department of Diagnostic and Biological Sciences, University of Minnesota
5 shared publicationsDarryl T. Hamamoto
University of Minnesota
4 shared publicationsEyup Akgün
Department of Medicinal Chemistry, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USA
4 shared publicationsGiuseppe Cataldo
Department of Diagnostic and Biological Sciences, School of Dentistry, University of Minnesota, Minneapolis, MN 55455, USA
4 shared publications
Latest Publications
- Open Access
- 5 June 2025
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 110 (12) , 3114-3118
Oral administration of a liquid containing nitrous oxide abolishes vaso-occlusive pain in mice with sickle cell disease
- 5 June 2025
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 110 (12) , 3114-3118
Open AccessOral administration of a liquid containing nitrous oxide abolishes vaso-occlusive pain in mice with sickle cell disease
- Open Access
- 26 December 2024
- Published by OAE Publishing Inc. in Extracellular Vesicles and Circulating Nucleic Acids
- Vol. 5 (4) , 785-7
The role of cancer cell-released extracellular vesicles: have we become closer to cancer pain treatment?
The effective management of cancer pain continues to be a challenge because of our limited understanding of cancer pain mechanisms and, in particular, how cancer cells interact with neurons to produce pain. In a study published in Pain , Inyang et al. used a mouse model of human papillomavirus (HPV1)-induced oropharyngeal squamous cell carcinoma to show a role for cancer cell-derived extracellular vesicles (cancer sEVs) in cancer pain. They found that inhibiting the release of sEVs reduced spontaneous and evoked pain behaviors, and that pain produced by sEVs is due to activation of TRPV1 channels. An innovative approach was the use of publicly available human RNA-sequencing data from unstimulated cultured human dorsal root ganglia (DRG) that were exposed to human head and neck squamous cell carcinoma (HNSCC)-derived sEVs to identify signaling pathways involved in the nascent translation associated with nociception. These studies further our understanding of functional interactions between cancer cells and neurons, and suggest an approach to identify novel targets for the treatment of cancer pain.
- 26 December 2024
- Published by OAE Publishing Inc. in Extracellular Vesicles and Circulating Nucleic Acids
- Vol. 5 (4) , 785-7
Open AccessThe role of cancer cell-released extracellular vesicles: have we become closer to cancer pain treatment?
The effective management of cancer pain continues to be a challenge because of our limited understanding of cancer pain mechanisms and, in particular, how cancer cells interact with neurons to produce pain. In a study published in Pain , Inyang et al. used a mouse model of human papillomavirus (HPV1)-induced oropharyngeal squamous cell carcinoma to show a role for cancer cell-derived extracellular vesicles (cancer sEVs) in cancer pain. They found that inhibiting the release of sEVs reduced spontaneous and evoked pain behaviors, and that pain produced by sEVs is due to activation of TRPV1 channels. An innovative approach was the use of publicly available human RNA-sequencing data from unstimulated cultured human dorsal root ganglia (DRG) that were exposed to human head and neck squamous cell carcinoma (HNSCC)-derived sEVs to identify signaling pathways involved in the nascent translation associated with nociception. These studies further our understanding of functional interactions between cancer cells and neurons, and suggest an approach to identify novel targets for the treatment of cancer pain.
- Open Access
- 1 September 2023
- Published by Wolters Kluwer Health in Pain Reports
- Vol. 8 (5) , e1097
Increases in local skin temperature correlate with spontaneous foot lifting and heat hyperalgesia in both incisional inflammatory models of pain
Background: This study investigated if a localized increase in skin temperature in rat models of incisional and inflammatory pain correlates with the intensity of spontaneous and evoked pain behaviors. Methods: Anesthetized rats received either a 20-mm longitudinal incision made through the skin, fascia, and muscle of the plantar hind paw or an injection of complete Freund adjuvant into the plantar hind paw of anesthetized rats to induce local inflammation. Spontaneous and evoked pain behaviors were assessed, and changes in skin temperature were measured using a noncontact infrared thermometer. Results: There were no differences in skin temperature between the ipsilateral and contralateral hind paw before the incision or inflammation. Skin temperature increased at 2 hours after hind paw plantar incision or 1 day after inflammation of the affected paw, which gradually returned to baseline by the first day and fourth days after treatment, respectively. The increase in skin temperature correlated with the intensity of spontaneous pain behaviors and heat but not with mechanical allodynia. Conclusions: Our results suggest that a simple measurement of localized skin temperature using a noncontact infrared thermometer could measure the extent of spontaneous pain behaviors and heat hyperalgesia following plantar incision or inflammation in animals. In the absence of a reliable objective marker of pain, these results are encouraging. However, studies are warranted to validate our results using analgesics and pain-relieving interventions, such as nerve block on skin temperature changes.
- 1 September 2023
- Published by Wolters Kluwer Health in Pain Reports
- Vol. 8 (5) , e1097
Open AccessIncreases in local skin temperature correlate with spontaneous foot lifting and heat hyperalgesia in both incisional inflammatory models of pain
Background: This study investigated if a localized increase in skin temperature in rat models of incisional and inflammatory pain correlates with the intensity of spontaneous and evoked pain behaviors. Methods: Anesthetized rats received either a 20-mm longitudinal incision made through the skin, fascia, and muscle of the plantar hind paw or an injection of complete Freund adjuvant into the plantar hind paw of anesthetized rats to induce local inflammation. Spontaneous and evoked pain behaviors were assessed, and changes in skin temperature were measured using a noncontact infrared thermometer. Results: There were no differences in skin temperature between the ipsilateral and contralateral hind paw before the incision or inflammation. Skin temperature increased at 2 hours after hind paw plantar incision or 1 day after inflammation of the affected paw, which gradually returned to baseline by the first day and fourth days after treatment, respectively. The increase in skin temperature correlated with the intensity of spontaneous pain behaviors and heat but not with mechanical allodynia. Conclusions: Our results suggest that a simple measurement of localized skin temperature using a noncontact infrared thermometer could measure the extent of spontaneous pain behaviors and heat hyperalgesia following plantar incision or inflammation in animals. In the absence of a reliable objective marker of pain, these results are encouraging. However, studies are warranted to validate our results using analgesics and pain-relieving interventions, such as nerve block on skin temperature changes.
- Open Access
- 16 June 2023
- Published by Elsevier in Neuroscience
- Vol. 526, 1-12
Descending Facilitation of Nociceptive Transmission From the Rostral Ventromedial Medulla Contributes to Hyperalgesia in Mice with Sickle Cell Disease
- 16 June 2023
- Published by Elsevier in Neuroscience
- Vol. 526, 1-12
Open AccessDescending Facilitation of Nociceptive Transmission From the Rostral Ventromedial Medulla Contributes to Hyperalgesia in Mice with Sickle Cell Disease
- 16 February 2023
- Published by Elsevier in Neuroscience
- Vol. 516, 54-61
MMG22 Potently Blocks Hyperalgesia in Cisplatin-treated Mice
- 16 February 2023
- Published by Elsevier in Neuroscience
- Vol. 516, 54-61
MMG22 Potently Blocks Hyperalgesia in Cisplatin-treated Mice
- Open Access
- 20 October 2022
- Published by American Society of Hematology in Blood
- Vol. 140 (16) , 1826-1830
A model of painful vaso-occlusive crisis in mice with sickle cell disease
In order to better understand mechanisms underlying acute pain during vaso-occlusive crises (VOCs) in patients with sickle cell disease, Khasabova et al report on a clinically relevant model in mice where VOC is stimulated by exposure to cold. Cold exposure produces robust hyperalgesia, stasis, hypoxia, elevated heart rate, and increased levels of the endocannabinoid 2-AG and its synthesizing enzyme, DAGLβ, in plasma and blood cells, respectively. Blocking DAGLβ prevents the development of hyperalgesia. Collectively, these data point to 2-AG signaling as a targetable mediator of VOC pain.
- 20 October 2022
- Published by American Society of Hematology in Blood
- Vol. 140 (16) , 1826-1830
Open AccessA model of painful vaso-occlusive crisis in mice with sickle cell disease
In order to better understand mechanisms underlying acute pain during vaso-occlusive crises (VOCs) in patients with sickle cell disease, Khasabova et al report on a clinically relevant model in mice where VOC is stimulated by exposure to cold. Cold exposure produces robust hyperalgesia, stasis, hypoxia, elevated heart rate, and increased levels of the endocannabinoid 2-AG and its synthesizing enzyme, DAGLβ, in plasma and blood cells, respectively. Blocking DAGLβ prevents the development of hyperalgesia. Collectively, these data point to 2-AG signaling as a targetable mediator of VOC pain.
- Open Access
- 26 May 2022
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 108 (3) , 859-869
Inhibition of DAGLβ as a therapeutic target for pain in sickle cell disease
Sickle cell disease (SCD) is the most common inherited disease. Pain is a key morbidity of SCD and opioids are the main treatment but their side effects emphasize the need for new analgesic approaches. Humanized transgenic mouse models have been instructive in understanding the pathobiology of SCD and mechanisms of pain. Homozygous (HbSS) Berkley mice express >99% human sickle hemoglobin and several features of clinical SCD including hyperalgesia. Previously, we reported that the endocannabinoid 2-arachidonoylglycerol (2-AG) is a precursor of the pro-nociceptive mediator prostaglandin E2-glyceryl ester (PGE2-G) which contributes to hyperalgesia in SCD. We now demonstrate the causal role of 2-AG in hyperalgesia in sickle mice. Hyperalgesia in HbSS mice correlated with elevated levels of 2-AG in plasma, its synthesizing enzyme diacylglycerol lipase β (DAGLβ) in blood cells, and with elevated levels of PGE2 and PGE2-G, pronociceptive derivatives of 2-AG. A single intravenous injection of 2-AG produced hyperalgesia in non-hyperalgesic HbSS mice, but not in control (HbAA) mice expressing normal human HbA. JZL184, an inhibitor of 2-AG hydrolysis, also produced hyperalgesia in non-hyperalgesic HbSS or hemizygous (HbAS) mice, but did not influence hyperalgesia in hyperalgesic HbSS mice. Systemic and intraplantar administration of KT109, an inhibitor of DAGLβ, decreased mechanical and heat hyperalgesia in HbSS mice. The decrease in hyperalgesia was accompanied by reductions in 2-AG, PGE2 and PGE2-G in the blood. These results indicate that maintaining the physiological level of 2-AG in the blood by targeting DAGLβ may be a novel and effective approach to treat pain in SCD.
- 26 May 2022
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 108 (3) , 859-869
Open AccessInhibition of DAGLβ as a therapeutic target for pain in sickle cell disease
Sickle cell disease (SCD) is the most common inherited disease. Pain is a key morbidity of SCD and opioids are the main treatment but their side effects emphasize the need for new analgesic approaches. Humanized transgenic mouse models have been instructive in understanding the pathobiology of SCD and mechanisms of pain. Homozygous (HbSS) Berkley mice express >99% human sickle hemoglobin and several features of clinical SCD including hyperalgesia. Previously, we reported that the endocannabinoid 2-arachidonoylglycerol (2-AG) is a precursor of the pro-nociceptive mediator prostaglandin E2-glyceryl ester (PGE2-G) which contributes to hyperalgesia in SCD. We now demonstrate the causal role of 2-AG in hyperalgesia in sickle mice. Hyperalgesia in HbSS mice correlated with elevated levels of 2-AG in plasma, its synthesizing enzyme diacylglycerol lipase β (DAGLβ) in blood cells, and with elevated levels of PGE2 and PGE2-G, pronociceptive derivatives of 2-AG. A single intravenous injection of 2-AG produced hyperalgesia in non-hyperalgesic HbSS mice, but not in control (HbAA) mice expressing normal human HbA. JZL184, an inhibitor of 2-AG hydrolysis, also produced hyperalgesia in non-hyperalgesic HbSS or hemizygous (HbAS) mice, but did not influence hyperalgesia in hyperalgesic HbSS mice. Systemic and intraplantar administration of KT109, an inhibitor of DAGLβ, decreased mechanical and heat hyperalgesia in HbSS mice. The decrease in hyperalgesia was accompanied by reductions in 2-AG, PGE2 and PGE2-G in the blood. These results indicate that maintaining the physiological level of 2-AG in the blood by targeting DAGLβ may be a novel and effective approach to treat pain in SCD.
- 24 March 2021
- Published by Elsevier in Neuroscience Letters
- Vol. 753, 135845
The role of PPARγ in chemotherapy-evoked pain
- 24 March 2021
- Published by Elsevier in Neuroscience Letters
- Vol. 753, 135845
The role of PPARγ in chemotherapy-evoked pain
- 1 September 2020
- Published by Wolters Kluwer Health in Pain
- Vol. 161 (9) , 2041-2057
The bivalent ligand, MMG22, reduces neuropathic pain after nerve injury without the side effects of traditional opioids
Functional interactions between the mu opioid receptor (MOR) and the metabotropic glutamate receptor 5 (mGluR5) in pain and analgesia have been well established. MMG22 is a bivalent ligand containing MOR agonist (oxymorphamine) and mGluR5 antagonist (MPEP) pharmacophores tethered by a 22-atom linker. MMG22 has been shown to produce potent analgesia in several models of chronic inflammatory and neuropathic pain (NP). This study assessed the efficacy of systemic administration of MMG22 at reducing pain behavior in the spared nerve injury (SNI) model of NP in mice, as well as its side-effect profile and abuse potential. MMG22 reduced mechanical hyperalgesia and spontaneous ongoing pain after SNI, with greater potency early (10 days) as compared to late (30 days) after injury. Systemic administration of MMG22 did not induce place preference in naive animals, suggesting absence of abuse liability when compared to traditional opioids. MMG22 also lacked the central locomotor, respiratory, and anxiolytic side effects of its monomeric pharmacophores. Evaluation of mRNA expression showed the transcripts for both receptors were colocalized in cells in the dorsal horn of the lumbar spinal cord and dorsal root ganglia. Thus, MMG22 reduces hyperalgesia after injury in the SNI model of NP without the typical centrally mediated side effects associated with traditional opioids.
- 1 September 2020
- Published by Wolters Kluwer Health in Pain
- Vol. 161 (9) , 2041-2057
The bivalent ligand, MMG22, reduces neuropathic pain after nerve injury without the side effects of traditional opioids
Functional interactions between the mu opioid receptor (MOR) and the metabotropic glutamate receptor 5 (mGluR5) in pain and analgesia have been well established. MMG22 is a bivalent ligand containing MOR agonist (oxymorphamine) and mGluR5 antagonist (MPEP) pharmacophores tethered by a 22-atom linker. MMG22 has been shown to produce potent analgesia in several models of chronic inflammatory and neuropathic pain (NP). This study assessed the efficacy of systemic administration of MMG22 at reducing pain behavior in the spared nerve injury (SNI) model of NP in mice, as well as its side-effect profile and abuse potential. MMG22 reduced mechanical hyperalgesia and spontaneous ongoing pain after SNI, with greater potency early (10 days) as compared to late (30 days) after injury. Systemic administration of MMG22 did not induce place preference in naive animals, suggesting absence of abuse liability when compared to traditional opioids. MMG22 also lacked the central locomotor, respiratory, and anxiolytic side effects of its monomeric pharmacophores. Evaluation of mRNA expression showed the transcripts for both receptors were colocalized in cells in the dorsal horn of the lumbar spinal cord and dorsal root ganglia. Thus, MMG22 reduces hyperalgesia after injury in the SNI model of NP without the typical centrally mediated side effects associated with traditional opioids.
- 25 August 2020
- Published by Elsevier in Neuroscience
- Vol. 446, 102-112
Topical Application of Loperamide/Oxymorphindole, Mu and Delta Opioid Receptor Agonists, Reduces Sensitization of C-fiber Nociceptors that Possess NaV1.8
- 25 August 2020
- Published by Elsevier in Neuroscience
- Vol. 446, 102-112
Topical Application of Loperamide/Oxymorphindole, Mu and Delta Opioid Receptor Agonists, Reduces Sensitization of C-fiber Nociceptors that Possess NaV1.8